Cassava Sciences' mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer's disease.

Company profile
Ticker
SAVA
Exchange
Website
CEO
Remi Barbier
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
PAIN THERAPEUTICS INC
SEC CIK
Corporate docs
Subsidiaries
Austin Innovation Park, LLC ...
IRS number
911911336
SAVA stock data
News

5 Short Squeeze Candidates To Watch This Week: Cassava Sciences Tops List, GameStop Short Interest And Cost To Borrow Rise
6 Jun 22
12 Health Care Stocks Moving In Tuesday's Intraday Session
31 May 22
5 Short Squeeze Candidates To Watch This Week: 2 Former SPACs Join Leaderboard With BigBear.AI Topping List
24 May 22
How Is The Market Feeling About Cassava Sciences?
12 May 22
Recap: Cassava Sciences Q1 Earnings
5 May 22
Press releases
Bragar Eagel & Squire, P.C. Is Investigating GoodRx, Cassava, Ebix, and the WWE and Encourages Investors to Contact the Firm
24 Jun 22
Thinking about buying stock in Tonix Pharmaceuticals, View, vTv Therapeutics, TherapeuticsMD, or Cassava Sciences?
1 Jun 22
Bragar Eagel & Squire, P.C. Is Investigating Medallion, Corcept, RBB, and Cassava and Encourages Investors to Contact the Firm
29 May 22
Global Psychedelics Market Is Expected To Reach $8 Billion By 2029
24 May 22
Bragar Eagel & Squire, P.C. Is Investigating Cassava, Dentsply Sirona, IonQ, and Singularity Future and Encourages Investors to Contact the Firm
22 May 22
Investment data
Securities sold
Number of investors
Calendar
5 May 22
26 Jun 22
31 Dec 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 209.69M | 209.69M | 209.69M | 209.69M | 209.69M | 209.69M |
Cash burn (monthly) | 7.91M | 6.04M | 5.94M | 3.93M | 7.84M | 4.29M |
Cash used (since last report) | 22.72M | 17.34M | 17.05M | 11.28M | 22.51M | 12.3M |
Cash remaining | 186.97M | 192.35M | 192.64M | 198.41M | 187.18M | 197.39M |
Runway (months of cash) | 23.6 | 31.8 | 32.4 | 50.5 | 23.9 | 46.1 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Jun 22 | Remi Barbier | Common Stock | Payment of exercise | Dispose F | No | No | 27.93 | 54,720 | 1.53M | 767,717 |
6 Jun 22 | Remi Barbier | Common Stock | Option exercise | Acquire M | No | No | 23.38 | 65,368 | 1.53M | 822,437 |
6 Jun 22 | Remi Barbier | Common Stock Common Stock | Option exercise | Dispose M | No | No | 23.38 | 65,368 | 1.53M | 0 |
27 May 22 | Nadav Friedmann | Common Stock | Payment of exercise | Dispose F | No | No | 26.66 | 21,498 | 573.14K | 70,534 |
27 May 22 | Nadav Friedmann | Common Stock | Payment of exercise | Dispose F | No | No | 26.66 | 3,071 | 81.87K | 92,032 |
27 May 22 | Nadav Friedmann | Common Stock | Option exercise | Acquire M | No | No | 23.38 | 24,513 | 573.11K | 95,103 |
27 May 22 | Nadav Friedmann | Common Stock | Option exercise | Acquire M | No | No | 23.38 | 3,501 | 81.85K | 70,590 |
27 May 22 | Nadav Friedmann | Common Stock Common Stock | Option exercise | Dispose M | No | No | 23.38 | 24,513 | 573.11K | 0 |
27 May 22 | Nadav Friedmann | Common Stock Common Stock | Option exercise | Dispose M | No | No | 23.38 | 3,501 | 81.85K | 0 |
25 Apr 22 | Remi Barbier | Common Stock | Option exercise | Acquire M | Yes | No | 16.31 | 4,669 | 76.15K | 376,112 |
Institutional ownership, Q1 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0 |
Total shares | 0 |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Financial report summary
?Competition
Abbott Laboratories • Mylan • AMGEN • Acura Pharmaceuticals • Biogen • Roche • Elite Pharmaceuticals • Endo Health Solutions • Novartis • Anavex Life SciencesContent analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
category, confined, County, CUNY, divert, dosage, enquiry, exploratory, federal, high, lawsuit, length, lingering, maximize, monthly, motion, nature, package, packaging, pending, percent, policy, population, preliminary, preserve, primary, publicly, Puerto, putative, quality, rational, rental, replaced, resolution, Rico, segment, staffing, stay, stayed, subsidiary, suite, typically, University, verification, volatility, York
Removed:
Additionally, ASU, beginning, beneficial, blinded, campaign, cognitively, compare, complexity, conclude, detected, drain, effort, FASB, fast, franchise, goal, independent, initiative, intact, intention, journal, lower, multiply, outdated, overt, Overview, quantitative, recently, reduce, redundant, remain, simple, Simplifying, superseded, supplemental, Topic, trillion, triple, tx, untreated, upcoming, young
Financial reports
Current reports
8-K
Submission of Matters to a Vote of Security Holders
9 May 22
8-K
Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program
5 May 22
8-K
Regulation FD Disclosure
26 Apr 22
8-K
Cassava Sciences Reports Full-year 2021 Financial Results and Operating Updates
27 Feb 22
8-K
Departure of Directors or Certain Officers
6 Jan 22
8-K
Cassava Sciences Reports Third Quarter 2021 Financial Results
10 Nov 21
8-K
Regulation FD Disclosure
3 Aug 21
8-K
Cassava Sciences Reports Second Quarter 2021 Financial Results
3 Aug 21
8-K
Entry into a Material Definitive Agreement
21 Jun 21
8-K
Cassava Sciences Announces the Appointment of
14 Jun 21
Registration and prospectus
S-8
Registration of securities for employees
10 Jun 22
424B5
Prospectus supplement for primary offering
11 Feb 21
S-3ASR
Automatic shelf registration
10 Feb 21
424B5
Prospectus supplement for primary offering
16 Nov 20
FWP
Free writing prospectus
13 Nov 20
424B5
Prospectus supplement for primary offering
12 Nov 20
424B2
Prospectus for primary offering
5 May 20
S-3/A
Shelf registration (amended)
9 Apr 20
S-3
Shelf registration
27 Mar 20
S-1
IPO registration
18 Dec 18
Other
EFFECT
Notice of effectiveness
6 May 20
CORRESP
Correspondence with SEC
30 Apr 20
CORRESP
Correspondence with SEC
8 Apr 20
UPLOAD
Letter from SEC
1 Apr 20
EFFECT
Notice of effectiveness
31 Jan 19
CORRESP
Correspondence with SEC
27 Jan 19
UPLOAD
Letter from SEC
20 Dec 18
EFFECT
Notice of effectiveness
30 Jul 17
UPLOAD
Letter from SEC
24 Apr 17
CT ORDER
Confidential treatment order
11 Apr 16
Ownership
4
CASSAVA SCIENCES / REMI BARBIER ownership change
7 Jun 22
4
CASSAVA SCIENCES / NADAV FRIEDMANN ownership change
31 May 22
4
CASSAVA SCIENCES / REMI BARBIER ownership change
25 Apr 22
4
CASSAVA SCIENCES / ROBERT Z GUSSIN ownership change
29 Mar 22
4
CASSAVA SCIENCES / SANFORD ROBERTSON ownership change
28 Mar 22
SC 13G
CASSAVA SCIENCES / VANGUARD ownership change
9 Feb 22
5
CASSAVA SCIENCES / Eric Schoen ownership change
3 Feb 22
5
CASSAVA SCIENCES / NADAV FRIEDMANN ownership change
3 Feb 22
SC 13G/A
CASSAVA SCIENCES / BARBIER REMI ownership change
3 Feb 22
SC 13G/A
CASSAVA SCIENCES / BlackRock ownership change
2 Feb 22
Transcripts
Reddit threads
What is a good SMALL but not widely known Stock/ Company with a good reputation, Kindness and active social media?
21 Jun 22
What are YOU considering buying, trading or investing in, this week? [Weekly Community Discussion]
19 Jun 22
Is Intel being dragged down by peers? August could be a great entry point. Discussion and my opinion
16 Jun 22
What Are Your Moves Tomorrow - June 16, 2022
15 Jun 22
Welcome To The Bear Market 🐻 🐻❄
12 Jun 22
This study trained machine-learning algorithms to identify the kind of accounting frauds spotted by short-sellers like muddywatersre, CitronResearch etc. in publicly-available earnings statements.
9 Jun 22
One penny stock that will blow up, please?
9 Jun 22
Daily Discussion - Friday June 03 2022
3 Jun 22
What Are Your Moves Tomorrow, June 01, 2022
31 May 22
Daily Discussion - Tuesday May 31 2022
31 May 22